Clinical Trial Update: Prevention of Heterotopic Ossification With Arcoxia After Total Hip Replacement [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating etoricoxib (Arcoxia) to prevent heterotopic ossification after total hip replacement has completed, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterotopic Ossification

Drugs mentioned

• Arcoxia (Etoricoxib)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Ossification, Heterotopic | Phase 4 | Status: COMPLETED | Results posted: 2013-09-02